Trevi Therapeutics is leveraging the dual mechanism of its drug Haduvio to treat chronic cough associated with idiopathic pulmonary fibrosis (IPF). The company plans to expand its treatment to other interstitial lung diseases (ILD) and refractory chronic cough. Positive Phase II trial results and ongoing pivotal studies support Trevi's shift to a specialty pharmaceutical platform focused on pulmonology. With competitors exiting the market, Trevi's strategy targets concentrated specialty networks, enabling efficient market entry and future growth without large commercial infrastructure, presenting a strong risk/reward profile for investors.
ServiceNow reported a 23% increase in subscription revenues to $3.8 billion, with key metrics like cRPO and RPO growing over 21% year-over-year. The company's professional services revenue remains small and does not significantly affect its stock out...
US spot Bitcoin ETFs saw a massive $517.2 million inflow on Wednesday, the largest since May 4, driven mainly by BlackRock's IBIT. This surge reflects growing institutional interest as Bitcoin's price recovers to around $64,000-$65,000. Spot Bitcoin ...
Frontline (FRO) is rated a Buy due to strong near-term cash flows and a conservative earnings floor, supporting a projected dividend yield of around 7% through 2028-29. Although its valuation is no longer cheap, with forward PE around 14x, the compan...
Walmart will report its fiscal second-quarter earnings, providing insight into U.S. consumer health amid a divided economy. The company, which focuses on value for lower-income shoppers while attracting higher-income customers, faces challenges from ...
A trader opened a $6 million 10x leveraged long position on Pump.fun (PUMP), signaling strong bullish confidence as the token rose 8.51% in 24 hours to around $0.003017. The position’s liquidation price is set at $0.002852, making this level critical...
